Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Feb;35(2):365–367. doi: 10.1128/aac.35.2.365

Fluconazole in the treatment of candidiasis in immunocompromised children.

C Viscoli 1, E Castagnola 1, F Fioredda 1, B Ciravegna 1, G Barigione 1, A Terragna 1
PMCID: PMC245006  PMID: 2024968

Abstract

Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candida parapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88%). Drug-related transaminase increases were observed in two cases (6%). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.

Full text

PDF
365

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bunin N., Camitta B. Oral fluconazole for treatment of disseminated fungal infection. Pediatr Infect Dis J. 1989 Jan;8(1):62–62. doi: 10.1097/00006454-198901000-00021. [DOI] [PubMed] [Google Scholar]
  2. Crislip M. A., Edwards J. E., Jr Candidiasis. Infect Dis Clin North Am. 1989 Mar;3(1):103–133. [PubMed] [Google Scholar]
  3. De Wit S., Weerts D., Goossens H., Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989 Apr 8;1(8641):746–748. doi: 10.1016/s0140-6736(89)92572-5. [DOI] [PubMed] [Google Scholar]
  4. Fisher M. A., Shen S. H., Haddad J., Tarry W. F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989 Sep;33(9):1443–1446. doi: 10.1128/aac.33.9.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fluconazole: a novel advance in therapy for systemic fungal infections. Dorado Beach, Puerto Rico, 8-9 October 1988. Proceedings. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S263–S389. [PubMed] [Google Scholar]
  6. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  7. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  8. Hanger D. P., Jevons S., Shaw J. T. Fluconazole and testosterone: in vivo and in vitro studies. Antimicrob Agents Chemother. 1988 May;32(5):646–648. doi: 10.1128/aac.32.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koren G., Lau A., Klein J., Golas C., Bologa-Campeanu M., Soldin S., MacLeod S. M., Prober C. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988 Sep;113(3):559–563. doi: 10.1016/s0022-3476(88)80653-x. [DOI] [PubMed] [Google Scholar]
  11. Meunier F., Aoun M., Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S364–S368. doi: 10.1093/clinids/12.supplement_3.s364. [DOI] [PubMed] [Google Scholar]
  12. Robinson P. A., Knirsch A. K., Joseph J. A. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S349–S363. doi: 10.1093/clinids/12.supplement_3.s349. [DOI] [PubMed] [Google Scholar]
  13. Starke J. R., Mason E. O., Jr, Kramer W. G., Kaplan S. L. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987 Apr;155(4):766–774. doi: 10.1093/infdis/155.4.766. [DOI] [PubMed] [Google Scholar]
  14. Turner R. B., Donowitz L. G., Hendley J. O. Consequences of candidemia for pediatric patients. Am J Dis Child. 1985 Feb;139(2):178–180. doi: 10.1001/archpedi.1985.02140040080032. [DOI] [PubMed] [Google Scholar]
  15. Viscoli C., Castagnola E., Corsini M., Gastaldi R., Soliani M., Terragna A. Fluconazole therapy in an underweight infant. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):925–926. doi: 10.1007/BF01963785. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES